CARDIFF ONCOLOGY, INC. Share-based Payment Arrangement, Accelerated Cost
CARDIFF ONCOLOGY, INC. (CRDF) reported Share-based Payment Arrangement, Accelerated Cost of $100.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost · last filed 2024-02-29
- CARDIFF ONCOLOGY, INC. share-based payment arrangement, accelerated cost for fiscal 2023 was $100.00K, a 0.00% change from fiscal 2022.
- CARDIFF ONCOLOGY, INC. share-based payment arrangement, accelerated cost for fiscal 2022 was $100.00K, a 83.33% decline from fiscal 2021.
- CARDIFF ONCOLOGY, INC. share-based payment arrangement, accelerated cost for fiscal 2021 was $600.00K.
| Period end | Share-based Payment Arrangement, Accelerated Cost 12 month |
|---|---|
| 2023-12-31 | $100.00K 10-K · filed 2024-02-29 |
| 2022-12-31 | $100.00K 10-K · filed 2023-03-02 |
| 2021-12-31 | $600.00K 10-K · filed 2023-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |